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Abstract: Alcohol is a commonly used drug worldwide. Epidemiological studies have 
identified alcohol consumption as a factor that may either positively or negatively 
influence many diseases including cardiovascular disease, certain cancers and dementia. 
Often there seems to be a differential effect of various drinking patterns, with frequent 
moderate consumption of alcohol being salutary and binge drinking or chronic abuse   
being deleterious to one’s health. A better understanding of the cellular and molecular 
mechanisms mediating the many effects of alcohol consumption is beginning to emerge, as 
well as a clearer picture as to whether these effects are due to the direct actions of alcohol 
itself, or caused in part by its metabolites, e.g., acetaldehyde, or by incidental components 
present in the alcoholic beverage (e.g., polyphenols in red wine). This review will discuss 
evidence to date as to how alcohol (ethanol) might affect atherosclerosis that underlies 
cardiovascular and cerebrovascular disease, and the putative mechanisms involved, 
focusing on vascular endothelial and smooth muscle cell effects.  
Keywords: alcohol; ethanol; cardiovascular; atherosclerosis; endothelial cell; vascular 
smooth muscle; signaling; mechanisms 
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1. Introduction/Epidemiological Evidence and Animal Study Evidence 
Epidemiologic studies that examine patterns of health and disease and associated factors in a 
population, point to a complex association between alcohol consumption and cardiovascular disease. 
With few exceptions, studies from several countries demonstrate a 20–40% lower cardiovascular 
disease incidence among drinkers of alcoholic beverages compared with non-drinkers. But what level 
of consumption is most beneficial and does drinking pattern and/or beverage choice matter? The 
general consensus currently is that compared with abstinence, frequent moderate consumption of 
alcohol is associated with the lowest risk for coronary heart disease incidence and mortality [1,2]. For 
example, 1–2 drinks per day is a negative risk factor for atherosclerosis and its clinical sequelae 
myocardial infarction and ischemic stroke [3]. On the other hand binge or heavy episodic drinking, 
defined in the USA as consuming 5 or more drinks in a relatively short time period, is associated with 
increased cardiovascular disease and associated mortality [4–6]. In terms of beverage choice, some 
studies report equal effects of wine, beer or liquor on cardiovascular disease risk [3,7], while other 
studies support a preferential red wine protective effect, attributable to both the alcohol (ethanol) and 
the polyphenolic antioxidant content, in particular resveratrol [8,9]. Moreover, some white wines are 
also reportedly cardioprotective, believed to be due to the presence of tyrosol and hydroxytyrosol [10–12]. 
In addition to epidemiological studies, moderate alcohol consumption has been shown to prevent 
the development and progression of atherosclerosis in a variety of animal/mouse models (C57 
hyperlipidemic mice) [13,14], (LDL receptor knockout (LDLR −/−) mice) [15], (ligation injury) [16]. 
A recent study in mice demonstrated differential effects of daily moderate and 2-day binge ethanol 
drinking (good and bad, respectively) on atherosclerotic plaque development, body weight gain and 
low density lipoprotein (LDL)-cholesterol levels in ligated Apolipoprotein E (ApoE) knockout (−/−) 
mice, in apparent agreement with epidemiologic findings in humans [17,18]. Conversely, Bentzon et al. 
reported that neither ethanol nor red wine affected established atherosclerotic plaques in ApoE −/−  
mice [19]. Similarly, beer consumption did not alter the development of atherosclerosis in mice [20]. 
Reasons for these conflicting results likely include different experimental variables such as the strain 
of mouse [21], type of model (e.g., ApoE −/−  vs. LDLR −/−  vs. ligation injury vs. endothelial 
denudation) and diet (e.g., differences in fat and cholate content [22]) used, as well as the stage of 
lesion development assessed. Mouse models of accelerated atherosclerosis, while not perfectly 
replicating the complexity of the human disease, nevertheless remain useful in the investigation of the 
pathogenesis of atherosclerosis as well as understanding how alcohol consumption may affect it, as 
long as care is taken in extrapolating results to humans. Of note in the alcohol research field is the 
variety of units used to describe alcohol treatment and or levels achieved, especially in animal studies; 
g/kg, mg, g%, millimolar, etc. This sometimes makes it difficult to accurately compare results from 
different studies as well as to relate the experimental conditions to levels of consumption in humans. 
For reference, in the USA 1 unit of alcohol (i.e., 12 oz beer, 5 oz of wine or 1.5 oz of liquor) contains 
14 g of pure alcohol and would give rise to a blood alcohol content in the range 0.02–0.03%, 
equivalent to approximately 5 mM. (The blood concentration considered legally impairing is   
0.08% v/v, which is about 17 mM). Ethanol (EtOH) is the type of alcohol found in alcoholic beverages 
and is used interchangeably with alcohol in this article. 
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2. Atherosclerosis 
Atherosclerosis, a chronic inflammatory condition in which the artery wall thickens as a result of 
the accumulation of cholesterol, macrophages and smooth muscle cells (SMC), ultimately restricting 
blood flow through the artery, is the main pathologic condition underlying coronary artery and 
cerebrovascular disease leading to heart attack and stroke, respectively. In the pathogenesis of 
atherosclerosis (reviewed in [23–26]), increases in plasma low density lipoprotein (LDL) leads to a 
proportional increase in the entry of cholesterol laden LDL particles into the arterial wall across a 
“compromised” endothelial monolayer, where it accumulates. Once there, it can become oxidized, 
possibly by free radical production from adjacent endothelium, smooth muscle cells or an isolated 
macrophage [27–30]. Oxidized LDL has numerous effects on a variety of cells, many of which are 
believed to cumulatively exacerbate atherothrombosis ([31] for review). These include promotion of 
monocyte adhesion and infiltration to the intima by causing production of monocyte chemotactic 
protein-1 (MCP-1) by endothelium and expression by endothelium of monocyte-binding proteins 
including intercellular adhesion molecule-1 (ICAM-1), foam cell formation following uptake of 
oxidized LDL via scavenger receptors (SR-A type I and II and CD36), and stimulation of the migration 
of medial SMC into the intima where they proliferate in response to growth factors such as platelet 
derived growth factor (PDGF) [23,25]. In the intima, SMC produce extracellular matrix molecules 
including collagen and elastin. The most common clinical complication of atherosclerosis occurs upon 
plaque rupture which allows blood components to come into contact with plaque lipids and tissue 
factor, resulting in thrombus formation. It is obvious then that there are many steps in atherogenesis 
that, were they affected by alcohol, might affect plaque development and subsequently myocardial 
infarction or stroke. Recent articles have reviewed alcohol’s effects on lipids, fibrinolysis and 
inflammation [32,33]. As endothelial dysfunction, together with the migration and proliferation of 
normally quiescent SMC plays a fundamental role in atherogenesis, we will focus in this review on 
alcohol effects on these two cell types.  
It should be noted that with respect to alcohol and the vasculature in general, the majority of studies 
have focused on arterial effects, as these are most relevant to cardiovascular disease. However, some 
studies have addressed the relationship between alcohol consumption and risk of venous thrombosis 
and venous thromboembolism (VTE). Pahor et al. reported that low to moderate alcohol consumption 
was associated with a decreased risk of deep vein thrombosis and pulmonary embolism in a cohort of 
people aged 68 years or older [34]. Pomp et al. came to a similar conclusion finding that alcohol 
consumption was associated with a reduced risk of venous thrombosis, an effect more pronounced in 
women, and one which may be mediated by decreased fibrinogen levels [35]. A more recent study 
attempted to dissect out the effect of different types of alcoholic beverage and drinking pattern and 
found that whereas liquor consumption and binge drinking was associated with an increased risk of 
VTE, wine drinking was associated with a reduced risk [36]. Thus, similar to alcohol’s effect on 
cardiovascular disease, its effect on VTE may depend on the pattern of consumption, as well as the 
type of alcoholic beverage consumed. 
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3. Alcohol and Nitric Oxide (NO) 
Nitric oxide (NO), also known as endothelium-derived relaxing factor (EDRF), is a key regulatory 
signaling molecule in the vasculature [37]. It is synthesized by the heme-containing, calcium and 
calmodulin-dependent enzyme nitric oxide synthase in endothelial cells (eNOS) from L-arginine in a 
reaction that produces stoichiometric amounts of L-citrulline [37,38]. Activation of NOS and release of 
NO results in stimulation of a soluble guanylyl cyclase leading to a profound increase in intracellular 
cyclic guanosine monophosphate (cGMP) levels within most target cells [38]. NO has a wide range of 
actions important in maintaining vascular homeostasis. In addition to causing vasodilation, it has 
antiproliferative, antioxidant and anti-inflammatory properties that inhibit atherogenesis ([39] for 
recent review). Common risk factors for atherosclerosis such as hypercholesterolemia, hypertension, 
smoking and diabetes mellitus are associated with reduced NO in the arterial wall. Because of these 
findings, numerous therapies have been investigated based on enhancing NO release, thereby reversing 
endothelial dysfunction and preventing atherogenesis.  
Researchers have wondered whether moderate alcohol consumption mediates some of its 
cardioprotective effects by stimulating NO, and conversely, whether binge drinking diminishes NO 
availability. Initial studies in cultured bovine aortic endothelial cells (BAEC) and human umbilical 
vein endothelial cells (HUVEC) reported that ethanol treatment increased NO production by enhancing 
NOS activity [40–42]. Abou-Agag et al. fed rats alcohol at moderate levels for 8 weeks before 
evaluating NO production and post-ischemic myocardial function and vascular relaxation ex vivo [43]. 
Their results indicated that moderate alcohol consumption increased the expression of eNOS protein in 
the vasculature and NO metabolites in the blood, an effect associated with enhanced postischemic 
myocardial systolic and diastolic function as well as attenuated ischemia-induced coronary vascular 
resistance [43]. Kleinhenz et al. published similar findings looking at aortic NOS expression, NO 
production and relaxation to acetylcholine in alcohol fed rats [44]. There is some evidence for gender 
differences in NOS-dependent vascular responsiveness to alcohol consumption, but this seems to involve 
inducible isoform NOS (iNOS) [45]. Of interest, male Fisher rats treated chronically (12 weeks) with 
high “abuse” levels (4 g/kg) of alcohol daily via orogastric tube developed hypertension, impaired 
vascular relaxation, reduced vascular eNOS expression, and evidence of increased vascular oxidative 
stress [46,47]. It is apparent that the dose and length of EtOH exposure, and cell type are the main 
factors affecting EtOH effects on NO production. Polikandriotis et al. reported that chronic   
ethanol ingestion increased NO release from pulmonary endothelial cells by a mechanism involving 
phosphatidylinositol 3-kinase (PI3K)-mediated increases in eNOS expression and increases in   
protein-protein interactions between eNOS and hsp90 [48]. In female rats, ethanol increased 
myocardial expressions of eNOS and its upstream regulators, PI3K and Akt (also known as protein 
kinase B), and plasma endotoxin and nitrite/nitrate were increased by ethanol [49]. 
Human studies show similar results; e.g., ethanol and red wine consumption acutely increased the 
production of NO in healthy subjects [50]. However, in a recent study comparing the effect of water, 
red wine, beer and vodka in healthy young subjects Huang et al. found that only red wine affected 
endothelial function (determined by flow-mediated vasodilation) and significantly increased plasma 
levels of nitric oxide [51]. Overall however, most studies in cells, animals and human subjects show a 
beneficial effect of moderate ethanol treatment on NO. A recent paper sheds more light on the Nutrients 2012, 4  301 
 
 
molecular mechanisms that may be involved [52]. Using human aortic endothelial cells (HAEC), they 
showed that rapid activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2), a key enzyme in 
ethanol metabolism, was involved in ethanol-induced eNOS activation by preventing reactive oxygen 
species (ROS) accumulation. ROS are implicated in atherosclerosis via inactivation of NO. Moreover, 
ethanol-induced ALDH2 activation was dependent on its acetylation modification by NAD-dependent 
deacetylase sirtuin-3  (SIRT3) inactivation, the latter due to a reduced NAD
+/NADH ratio in 
mitochondria [52]. Kuhlmann et al. reported that EtOH directly activates Ca
2+-activated potassium 
channels in HUVEC, leading to increased production of NO (at EtOH concentrations of 10–50 mM) [53]. 
Higher concentrations of EtOH (100 and 150 mM) significantly reduced NO synthesis [53]. Taken 
together, these studies are supportive of a protective effect of moderate alcohol and a deleterious effect 
of alcohol abuse via differential modulation of NOS activity and NO production in the vasculature. 
Changes in NO levels may partly explain the variable dilatory and constrictive effects reported for 
alcohol in different vascular beds [54–57]. Other mechanisms likely include ethanol-induced changes 
in the levels of the vasodilator prostacyclin (PGI2) [58] or the potent vasoconstrictor endothelin-1 [59], 
as well as changes in intracellular Ca
2+ [54,60,61] and Mg
2+ levels [62]. With respect to vasoreactivity 
and alcohol, once again there is evidence of opposite effects of low-moderate (vasodilatory) vs. high 
consumption (vasoconstrictive) [62]. 
4. Endothelial Progenitor Cells 
Evidence indicates that the injured endothelial monolayer may be regenerated by circulating bone 
marrow-derived endothelial progenitor cells (EPC), which accelerate re-endothelialization and protect 
against the initiation and progression of atherosclerosis [63,64]. Higher circulating levels of progenitor cells 
reflect greater repair capacity and have been shown to reduce the progression of atherosclerosis [65]. 
Of interest, a handful of recent studies suggest that alcohol consumption may increase the number of 
circulating EPC. Moderate red wine consumption improved neovascularization and blood flow 
recovery after ischemia in hypercholesterolemic mice and had a positive effect on EPC number and 
functional activity [66]. Huang et al. reported that red wine consumption by healthy subjects enhanced 
circulating EPC levels and improved EPC functions by modifying NO bioavailability [51]. In a mouse 
model of atherosclerosis (i.e., angiotensin II infusion in ApoE −/−) Gil-Bernabe et al. demonstrated 
that the low-dose ethanol treatment group had fewer atheromatous lesions, and increased secretion of 
stromal cell-derived factor-1 (SDF-1) with subsequent enhanced mobilization of progenitor cells, 
compared to the no alcohol controls [67]. Collectively, these studies support a modulatory effect of 
ethanol and/or polyphenols on EPC that may be anti-atherogenic. 
5. Alcohol and Reactive Oxygen Species (ROS). Alcohol: Prooxidant or Antioxidant? 
Increased production of reactive oxygen species (ROS) contributes to mechanisms of 
vascular/endothelial dysfunction and atherosclerosis [68,69]. Oxidative stress is mainly caused by an 
imbalance between the activity of endogenous pro-oxidative enzymes (such as NADPH oxidase, 
xanthine oxidase, or the mitochondrial respiratory chain) and anti-oxidative enzymes (such as 
superoxide dismutase, glutathione peroxidase, heme oxygenase, thioredoxin peroxidase/peroxiredoxin, 
catalase, and paraoxonase) in favor of the former. ROS may play a role in mediating alcohol’s various Nutrients 2012, 4  302 
 
 
effects, particularly in relation to its vasorelaxant effect and its protective effect against ischemia 
reperfusion injury. 
Rocha et al. recently reported that scavenging of superoxide anion (O2
−) and hydrogen peroxide 
(H2O2), both important ROS in the vascular wall, prevented ethanol-induced aortic relaxation, 
suggesting that the response was mediated, in part, by oxidative stress [70]. Their data further 
suggested that ROS generation triggers the activation of the NO–cGMP pathway, which in turn 
increases NO generation and relaxation [70]. These findings are supportive of a redox-sensitive and 
NO-dependent signaling mechanism underlying low to moderate ethanol-induced vascular relaxation. 
On the other hand, chronic alcohol abuse is associated with hypertension in animals and humans [45] 
and pharmacological (high) doses of ethanol induce vasoconstriction in aortic ring studies via   
redox-sensitive and cyclooxygenase-dependent signaling [60].  
Oxidative stress induced by ROS plays an important role in the pathogenesis of ischemia/ 
reperfusion injury. The regular moderate consumption of alcoholic beverages is believed to protect 
against ischemia-induced myocardial injury, in a manner similar to ischemic preconditioning (IPC), 
possibly by affecting the prooxidant/antioxidant balance. This area has been thoroughly reviewed 
previously [71,72]. 
6. Ethanol and Endothelial Proliferation, Migration and Angiogenesis 
Endothelial cell (EC) dysfunction and/or loss, in response to a wide range of injurious stimuli   
(e.g., high levels of LDL, smoking, low shear stress, iatrogenic manipulation), resulting in compromise 
of the protective endothelial barrier is acknowledged as a key initiating step in atherogenesis [23]. 
Stimulation of EC proliferation and/or migration in this context by alcohol might therefore be 
perceived as cardiovascular protective. Indeed, ethanol treatment of cultured EC at levels consistent 
with moderate consumption enhanced their proliferation, migration, and network formation on 
Matrigel (an index of angiogenic activity) [73]. This pro-angiogenic effect of ethanol was mediated via 
stimulation of a novel Notch-Angiopoietin 1 signaling pathway in these cells and this study provided 
the first evidence of the Notch pathway as a novel mechanistic target for ethanol [73]. The Notch 
pathway is a signaling mechanism important in vascular development, playing a key role in vascular 
cell fate decisions [74,75]. Notch receptors are expressed on both EC and SMC and their role in adult 
vascular physiology has being unveiled by researchers over the last 15 years. Of note, the function of 
the Notch pathway in EC may be dependent on the endothelial type, and activation of different Notch 
receptors by different ligands may elicit opposing responses. For example, Notch signaling can either 
inhibit or stimulate EC proliferation and migration [73,76–78]. Similarly, Notch reportedly has both 
pro- [73,79] and anti-angiogenic [80–82] effects.  
Migration and proliferation of endothelial cells is central to angiogenesis, i.e., the growth of new 
capillary blood vessels. Diseases characterized by abnormal or excessive angiogenesis include cancer, 
psoriasis and rheumatoid arthritis. Diseases characterized by insufficient angiogenesis or vessel 
regression include Alzheimers disease, diabetes, stroke, ischemic heart disease and restenosis [83]. 
Thus, angiogenesis is beneficial in some clinical circumstances but maladaptive in other situations and 
control of angiogenesis therefore represents an area with rich therapeutic potential. With respect to 
cardiovascular disease specifically, the role of angiogenesis is complex as it can be beneficial or Nutrients 2012, 4  303 
 
 
deleterious depending on the context; e.g., collateral vessel formation in response to ischemia vs. 
intraplaque neovasculature, respectively. Many advanced atherosclerotic lesions are vascularized, 
especially the “vulnerable” plaque regions [84], by a network of capillaries that arise from the 
adventitial vasa vasorum [85]. Plaque angiogenesis seems to characterize the inflammatory, more 
“active” plaque rather than the calcified, more “inactive” plaque and a positive association between 
neovessel density and plaque rupture has been reported [86]. 
In contrast to plaque angiogenesis, compensatory or collateral angiogenesis (e.g., coronary 
collaterals) is a physiological process in response to occlusion ischemia. Collaterals are induced over a 
period of several days-weeks and require tissue ischemia from existing vascular stenosis. The process 
results in the formation of mature vessels (“natural bypasses”) that can compensate for the loss of 
perfusion following myocardial infarction or stroke. Thus, the development of a collateral circulation 
plays an important role in protecting tissues from ischemic damage and its stimulation has emerged as 
one of the principal approaches to therapeutic angiogenesis [87]. Interestingly, clinical observations 
detail substantial differences in the extent of collateralization among patients with coronary artery 
disease, with some individuals demonstrating marked abundance and others showing nearly complete 
absence of these vessels [87,88]. Factors responsible for the presence or absence of collateral 
circulation are poorly understood but genetic and lifestyle factors, such as alcohol consumption, are 
likely to play a role. A relationship between alcohol and angiogenesis has previously been 
investigated. Radek et al. showed that acute ethanol exposure inhibited angiogenesis in a murine 
model of wound healing [89]. On the other hand, several groups report a stimulatory effect of ethanol 
on angiogenesis (particularly in relation to tumorigenesis) in a variety of in vivo and in vitro  
models [73,90–94]. The mechanisms involved included ethanol stimulation of angiogenic growth 
factors such as vascular endothelial growth factor (VEGF) [90,92], basic fibroblast growth factor 
(bFGF) [92,93], and transforming growth factor beta (TGFβ)1 [93], while Qian et al. provided 
evidence of a signaling pathway linking ethanol-induced changes in cell division control protein   
42 homolog (Cdc42), H2O2, actin filaments and cell motility to in vitro angiogenesis [95]. Endothelial 
cell migration and proliferation are central to the process of new blood vessel formation and a biphasic 
effect of ethanol, whereby low dose ethanol (1–30 mM) stimulates and higher dose ethanol   
(30–100 mM) inhibits EC proliferation and migration has also been reported [53,96]. The role of NO 
in angiogenesis remains controversial with multiple lines of evidence for both pro-angiogenic and  
anti-angiogenic activity ([97] for review). As mentioned earlier, ethanol has been previously shown to 
modulate nitric oxide synthase (NOS) activity and NO production [40,41]. Of interest, in relation to 
coronary collateral formation, a recent study found an association between alcohol consumption and 
the presence of collaterals in patients with documented coronary artery disease[98]. 
7. Monocyte Chemotactic Protein-1 
Monocyte chemotactic protein-1 (MCP-1) plays an important role in the recruitment and activation 
of monocytes and thus in the development of atherosclerosis.  In response to several atherogenic 
stimulants such as oxidized LDL, platelet derived growth factor (PDGF) and interleukin-1β (IL-1β), 
MCP-1 is induced in endothelial cells, smooth muscle cells and monocytes [99]. MCP-1 mediates its 
biological activity mainly through interaction with an MCP-1 receptor, CCR2, (also known as C-C Nutrients 2012, 4  304 
 
 
chemokine receptor) on the surface of its target cells which include monocytes. This receptor belongs 
to the superfamily of G protein-coupled receptors with seven transmembrane domains. The important 
role of CCR2 in atherogenesis has been demonstrated in studies using gene knockout animal models; 
there was a marked decrease in atherosclerotic lesion formation in apo-E-null mice that lacked   
CCR2 [100] and increased CCR2 expression is evident in patients with hypercholesterolemia [101]. 
Several agents, including homocysteine and oxidized LDL, have been shown to affect CCR2 
expression [102]. An alcohol effect on MCP-1 and/or its receptor would therefore be of clinical 
interest/relevance, and it has been investigated in vitro and in vivo. In HUVEC, Cullen et al. 
demonstrated that although EtOH had no effect on monocyte CCR2 binding activity, it inhibited   
IL-1β-stimulated endothelial MCP-1 expression by decreasing MCP-1 mRNA stability, binding of the 
transcription factors nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1), and MCP-1 gene 
transcription [103]. These data suggest a possible mechanism whereby EtOH could block monocyte 
adhesion and subsequent recruitment to the sub endothelial space and thus inhibit atherogenesis. In 
apparent support of this hypothesis, moderate consumption of ethanol or de-alcoholized red wine over 
3 weeks by healthy subjects resulted in a significant inhibitory effect on MCP-1-induced migration of 
monocytes ex vivo and in vitro, with no effect on MCP-1 receptor expression [104]. However, in 
another study in healthy volunteers comparing the effect of different alcoholic beverages containing 
more or less polyphenols, Blanco-Colio et al. found that only beverages with the highest polyphenol 
content (e.g., red wine) inhibited plasma MCP-1 concentrations [105]. Similarly, Vazquez-Agnell et al. 
reported an inhibition of MCP-1 following sparkling wine (medium level polyphenol content) 
consumption but not gin (no polyphenol content) [106]. Taken together, these studies support an effect 
of both ethanol and polyphenols in modulating MCP-1 expression. Whether the MCP-1 inhibitory 
effect of alcoholic beverages is due primarily to the polyphenol content rather than the ethanol, per se, 
requires further investigation. 
Of note, the primary step in the metabolism of alcohol is its oxidation to acetaldehyde by the 
enzyme alcohol dehydrogenase (ADH). Acetaldehyde is rapidly converted to acetate by other enzymes 
and is eventually metabolized to carbon dioxide and water. Acetaldehyde itself has been shown to have 
multiple cardiovascular effects in vivo, including vasodilation, increased heart rate and decreased 
blood pressure [107]. In vitro, acetaldehyde increased monocyte adhesion to cultured EC and 
stimulated P-selectin and TNFα expression [108]. It is possible, particularly in binge drinking 
scenarios where elevated blood acetaldehyde levels have been reported [109], that some of the 
cardiovascular effects of alcohol consumption are due to a combination of the direct actions of ethanol 
itself in combination with effects due to its primary metabolite, acetaldehyde. The balance between 
ethanol and acetaldehyde levels may be an important factor to consider in the beneficial vs. deleterious 
effects of different drinking patterns [17].  
8. Smooth Muscle Cell (SMC) Differentiation/Phenotypic Switching and Vascular Disease 
In the adult, vascular smooth muscle cells (SMC) proliferate at an extremely low rate and their 
principal function is contraction and regulation of blood vessel diameter. Unlike either skeletal or 
cardiac muscle that are terminally differentiated, SMC within adult animals retain plasticity and can 
undergo reversible changes in phenotype in response to a variety of local environmental cues such as Nutrients 2012, 4  305 
 
 
growth factors or mechanical forces [110]. An example of this plasticity can be seen in response to 
vascular injury when SMC dramatically increase their rate of cell proliferation, migration and synthetic 
capacity (including the production of extracellular matrix components). There is a strong body of 
evidence that this “phenotypic switching” or “differentiation” plays a major role in a number of   
human diseases, in particular vascular proliferative pathologies including atherosclerosis and 
restenosis [111,112].  
Several groups have investigated the effect of alcohol on injury-induced vascular remodeling/intimal 
medial thickening that is driven predominately by a smooth muscle migratory and proliferative 
response. An ethanol-induced reduction in neointimal formation following balloon injury has been 
reported in rabbits and pigs [113–115]. This inhibition of intimal hyperplasia was observed following 
either local delivery of ethanol or alcohol feeding [113,114]. The preservation of arterial lumen 
diameter was achieved by decreasing neointimal proliferation in part by decreasing LDL oxidation in 
these animals. Emeson et al. demonstrated in mice fed a high fat diet that alcohol feeding not only 
inhibited the initial development of atherosclerotic lesions, but also inhibited the progression of 
existing lesions [14]. In a study using rabbit iliac arteries following balloon angioplasty, significant 
inhibition of SMC phenotype conversion from contractile to synthetic was observed following   
ethanol treatment that was indicative of an inhibition of SMC proliferation [113]. In the porcine   
balloon-overstretch model, perivascular administration of a single-dose ethanol reduced neointimal 
proliferation [116]. Moderate daily consumption of ethanol inhibited carotid intimal-medial thickening 
after ligation injury/flow reduction in mice [16,17], whereas 2 day/week binge alcohol consumption 
exacerbated it [17]. Moreover, in a retrospective cohort study involving 225 male patients,   
Niroomand et al. reported that alcohol intake (≥50 g alcohol/week) was associated with reduced 
restenosis after percutaneous transluminal coronary angioplasty (PTCA) and stent implantation in 
patients, and a lower rate of repeat angioplasty [117]. 
A number of studies employing isolated vascular SMC in culture confirm an anti-proliferative 
effect of alcohol in these cells. Ethanol dose-dependently inhibited serum-stimulated mitogenesis and 
proliferation in rat aortic SMC [118]. The activity of mitogen activated protein kinases (MAPKs), 
which play a key role in regulating SMC growth [119] was inhibited by ethanol in these cells [118]. A 
differential modulation of key cell cycle regulatory molecules by ethanol, including the induction of 
the cyclin-dependent kinase (Cdk) inhibitor p21
waf1/cip1, and inhibition of cyclin A, has also been 
reported and may be the mechanism by which ethanol inhibits G1→S phase progression of the cell 
cycle and thus SMC proliferation [120]. Inhibition of SMC growth by ethanol has also been correlated 
with a reduction in fibroblast growth factor (FGF)-dependent MAPK activation [121]. Lochner et al. 
demonstrated that the stimulatory effect of postprandial plasma on SMC proliferation was reduced 
significantly by the concomitant ingestion of ethanol in healthy subjects [122]. Of note, as NO itself is 
a potent inhibitor of vascular smooth muscle cell proliferation [123,124] ethanol may also affect 
vascular SMC growth indirectly via its stimulatory effect on endothelial cell NO production.  
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Notch, Vascular Injury and SMC Proliferation 
Notch receptors and downstream target genes (Hes, Hrt) are crucial in controlling adult vascular 
SMC growth, migration and apoptosis in vitro and in vivo [125–127]. Cyclic strain, due to pulsatile 
blood flow, modulates Notch receptor signaling and proliferation in vascular SMC [128]. Moreover, 
previous studies suggest that the expression of several Notch components, including receptors   
(Notch 1 and Notch 3), ligands (Jag1, Jag2) and target genes (Hrt-1 and Hrt-2) are altered after 
experimentally-induced vascular injury (balloon catheter denudation) [126,129,130] and in human 
atherosclerotic lesions [131]. Intimal hyperplasia after vascular injury was significantly decreased in 
Hrt 2 −/− mice [132] and SMC from Hrt 2 −/− mice revealed that these mutant cells proliferate at a 
reduced rate compared with wild-type cells while the over-expression of Hrt 1 or Hrt 2 in VSMC led to 
increased VSMC proliferation associated with reduced levels of the cyclin-dependent kinase inhibitors 
p21
waf1/cip1 (Cdkn1a) or p27
kip1 (Cdkn1b) [133]. Recently, Morrow et al. investigated whether 
modulation of Notch signaling may mediate alcohol’s inhibitory effect on SMC proliferation. They 
found that ethanol treatment selectively inhibited Notch 1 mRNA and decreased CBF-1/RBPjk 
promoter activity and Notch target gene expression, concomitant with inhibition of SMC proliferation 
in vitro [16]. Moreover, Notch 1 and HRT-1 expression induced after ligation injury, was inhibited by 
moderate alcohol feeding in mice [16]. Overexpression of constitutively active Notch 1 IC or hHRT-1 
prevented the ethanol-induced inhibition of SMC proliferation [16]. Thus, it appears that ethanol 
inhibits SMC proliferation by inhibiting Notch signaling in these cells [16], effects opposite to that 
reported in EC [73]. It is conceivable, however, that stimulation of EC proliferation together with 
simultaneous inhibition of SMC by ethanol would be synergistically protective against atherogenesis. 
In any case, these data indicate that ethanol has an intriguing differential effect on Notch signaling and 
growth, depending on the cell type. Further investigation is warranted to understand the mechanisms 
mediating these differential effects. 
In addition to proliferation, migration of SMC from the media to the intima is a prominent feature 
of atherogenesis. SMC migration requires degradation of the extracellular matrix (ECM) a process 
which involves the plasminogen/plasmin and matrix metalloproteinase (MMP) systems. Ethanol 
treatment inhibited basal and pulse pressure-induced migration of human SMC [134] by stimulating 
plasminogen activator inhibitor-1 (PAI-1) and concomitantly inhibiting MMP-2 and MMP-9 [135]. 
Analogously, moderate consumption of beer or alcoholic beverages in healthy subjects reduced   
MMP-2 plasma activity, with no effect on MMP-2 expression or antioxidant activity levels [136]. 
9. Molecular Mechanism of Action? 
Clearly, numerous biochemical and physiological effects of ethanol have been described over the 
past few decades. It is somewhat surprising then that relatively little is yet known about precisely how 
ethanol acts mechanistically to produce its many effects, cardiovascular or otherwise. While an 
“ethanol receptor” has not yet been identified, more information re ethanol’s molecular targets is 
slowly emerging (reviewed in [137]). Moreover, ethanol may act on membrane proteins by disrupting 
protein-lipid interactions. One hypothesis is that if this occurred relatively specifically in lipid rafts 
(i.e., membrane microdomains enriched in cholesterol and sphingomyelin) which are emerging as Nutrients 2012, 4  307 
 
 
important players in signal transduction because of their ability to concentrate and assemble signaling 
molecules, the movement of proteins into or out of rafts and therefore signaling through several 
receptors types, could be modulated [138]. In support of this, recent evidence supports a role for lipid 
rafts in the actions of ethanol on macrophage activation and TLR4 signaling [139,140]. More precise 
knowledge of ethanol’s molecular targets and/or mechanisms of action should lead to the development 
of therapeutic agents that can mimic the beneficial effects of alcohol and/or block its deleterious and 
intoxicating effects.  
Investigation of microRNAs (miRNAs) as possible targets for ethanol has also begun, particularly 
in relation to alcohol abuse and toxicity (reviewed in [141]), and may yield new information with 
respect to alcohol’s pleiotropic cardiovascular effects. miRNAs are small, non-coding RNAs that 
regulate gene expression by binding to complementary sequences within target mRNAs. They have 
been shown to play critical roles in a broad array of fundamental biologic processes including 
regulation of the cell cycle and cell differentiation [141], and they have been implicated in vascular 
pathology and atherosclerosis [142]. Distinct miRNA signatures have been reported in cardiovascular 
disease [143] and these may reasonably be considered as potential novel targets for alcohol and for 
therapeutic intervention.  
10. Conclusions 
Many epidemiologic studies demonstrate a complex association between alcohol consumption and 
cardiovascular disease, with frequent low-moderate consumption being protective and chronic abuse or 
binge drinking being exacerbatory. Research scientists have corroborated these population findings in 
animal models of atherosclerosis and vascular remodeling, and have attempted to drill down to the cell 
and molecular signaling mechanisms involved using cultured cells in vitro exposed to ethanol. 
Evidence exists for an alcohol modulation of many of the individual steps deemed crucial in the 
atherogenic process including effects on lipid levels, inflammation and oxidative stress, as well as the 
differential effects on endothelial cells and vascular smooth muscle cells reviewed here. Changes in 
vasoactive substance production, cell migration and growth, enzyme and ion channel activity, and 
several signaling pathways have been described in response to ethanol exposure. Alcohol’s impact on 
cardiovascular disease is, therefore, likely the cumulative result of several separate effects (Figure 1). 
Investigation into the specific molecular mechanisms mediating these responses continues and is 
warranted. New areas of research interest in the alcohol field include progenitor cell effects, 
modulation of lipid raft protein trafficking and miRNA gene regulation. Precise knowledge of 
ethanol’s molecular targets and/or mechanisms of action, together with an understanding of the impact 
of different patterns of consumption and types of alcoholic beverage on health and disease will help 
direct healthy drinking behavior and may aid the development of therapeutic agents that can mimic the 
beneficial effects of alcohol, ideally in the absence of its deleterious and intoxicating effects. 
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Figure 1. Steps in atherogenesis affected by ethanol are indicated by an asterix (*). 
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